18 Month $3.00 Price Target From AEGIS Capital Corp.
on July 23,2013 (almost 6 months ago)
Our business strategy is to apply our drug delivery technologies to improve existing drug compounds with proven efficacy and safety and, in conjunction with strategic development and distribution partners, reintroduce these drug compounds to the market as branded products with improved deliverability and efficacy.
Because we are developing improved formulations of currently marketed therapeutics, our products typically require fewer clinical trials to generate the safety and efficacy data needed to achieve regulatory approval than drug formulations that have not been previously marketed.
As a result, we believe we can accelerate development and reduce risk compared to traditional pharmaceutical and biotechnology companies.
Using the 505(b)(2) approach to obtain FDA approval, our products have the possibility of obtaining three years of market exclusivity